Takeda Pharmaceutical Company Limited
TAKWI
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -1.29% | -2.14% | 1.39% | 1.81% | 1.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.29% | -2.14% | 1.39% | 1.81% | 1.87% |
| Cost of Revenue | -1.77% | 1.04% | 4.56% | 4.24% | 9.65% |
| Gross Profit | -1.04% | -3.78% | -0.24% | 0.59% | -1.83% |
| SG&A Expenses | 0.47% | -0.89% | 1.04% | -0.55% | -0.87% |
| Depreciation & Amortization | -1.08% | 79.11% | -0.89% | -1.29% | -0.84% |
| Other Operating Expenses | -104.91% | 368.58% | -81.93% | 66.52% | -69.82% |
| Total Operating Expenses | -1.88% | 8.44% | -0.05% | 0.90% | -0.01% |
| Operating Income | 2.59% | -44.67% | 12.45% | 8.71% | 16.24% |
| Income Before Tax | -8.75% | -60.38% | 328.54% | 177.19% | 39.74% |
| Income Tax Expenses | 275.59% | 389.12% | 153.11% | 172.80% | 194.75% |
| Earnings from Continuing Operations | -43.13% | -86.47% | -1.61% | -30.01% | 7.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -43.34% | -24.35% | -17.00% | -58.04% | -60.63% |
| Net Income | -43.21% | -86.54% | -1.63% | -30.09% | 7.52% |
| EBIT | 2.59% | -44.67% | 12.45% | 8.71% | 16.24% |
| EBITDA | 0.60% | -26.60% | 4.94% | 2.84% | 7.11% |
| EPS Basic | -42.60% | -86.16% | -1.48% | -30.61% | 6.34% |
| Normalized Basic EPS | 11.84% | -55.25% | 10.81% | 9.25% | 34.99% |
| EPS Diluted | -43.64% | -86.70% | -3.07% | -32.06% | 5.32% |
| Normalized Diluted EPS | 12.22% | -55.25% | 9.86% | 8.15% | 33.83% |
| Average Basic Shares Outstanding | -0.04% | 0.32% | 0.69% | 0.99% | 1.00% |
| Average Diluted Shares Outstanding | 0.01% | -0.06% | 1.17% | 1.57% | 1.58% |
| Dividend Per Share | 2.22% | 2.22% | 1.44% | 1.44% | -2.89% |
| Payout Ratio | 0.88% | 6.95% | 0.09% | 0.40% | -0.10% |